In a recent industry roundtable hosted by 24/7 Biopharma, a panel of leaders examined how rising molecular complexity and shifting market dynamics are reshaping the drug development landscape (link to the article). Among the key takeaways, Henny Zijlstra, CCO at Ardena, highlighted that for biotech companies, success depends on partnering with an integrated CDMO to bridge the widening gap between scientific ambition and development reality.
For many biotech companies, the pressure to reach the clinic is higher than ever, yet the molecules themselves are becoming increasingly complex. In this environment, navigating early phase drug development requires more than just raw capacity, it demands a different approach to strategy and execution.
The Trap of Linear Handovers
Zijlstra pointed out that a primary cause of delay and budget inefficiency is the traditional, linear view of development. Many programs are still treated as a series of handovers between functions: from solid-state chemistry to formulation, then to manufacturing, and finally to bioanalysis.
This model inevitably creates gaps. According to Zijlstra, the most successful programs are those that break this linear cycle. Instead of shifting a molecule from one functional silo to the next, companies benefit from a model where formulation strategy, analytical insight, and regulatory thinking are connected from day one. This is where an integrated CDMO becomes a vital partner, ensuring that decisions are not made in isolation but are informed by continuous scientific dialogue.
Development Judgement over Speed
While speed is a common goal in the industry, Zijlstra warned against “moving fast without technical purpose.” Generating data quickly is useless if that data does not support the next critical decision.
A truly effective CDMO partnership is defined by the ability to help clients see around corners – identifying where technical or regulatory risk is likely to appear before it becomes a bottleneck. Whether a program requires rapid enabling work to reach the clinic or a deeper investigation into solubility, stability, or delivery technology, the priority must be protecting capital and timelines by making the right choices at the right stage.
Integrating Bioanalytical CRO Expertise
The complexity of modern modalities, such as lipid-based systems or complex injectables, requires a deep connection between formulation and measurement. Zijlstra highlighted that innovation is not about one technology in isolation, but about the ability to turn complex science into better development decisions.
This requires an integrated CDMO and bioanalytical CRO capability that works in concert. At Ardena, our approach is built on the philosophy that ‘we know bioanalysis’, not as a separate service line, but as a critical data stream that informs every development decision.
By aligning bioanalytical data with formulation strategy, teams can see patterns earlier, compare outcomes more effectively, and capture knowledge across workstreams. For biopharma companies, this integrated approach creates practical value: it ensures the work being done consistently supports the next regulatory or partnering milestone.
Conclusion
The core message shared by Zijlstra is that complex molecules need more than capacity, they need development judgement. Protecting a product’s potential in the early stages requires a plan that is technically sound, stage-appropriate, and built on continuous scientific integration. As the industry continues to evolve, the focus must remain on connecting the scientific dots to turn potential into clinical reality.
